GlassScriptPhysician profile
Nalin J Mehta
NPI 1720180334
$80,861.68
in general payments reported to CMS, 2019-2025
26 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $15K · 2021: $8,870 · 2022: $984 · 2023: $920 · 2024: $149 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069 · Consulting Fee: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.32 |
| Consulting Fee | $491.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $77,093.05 | 2019-2024 | Eylea |
| Eyepoint US, INC. | $564.84 | 2020-2023 | |
| Becton, Dickinson and Company | $491.67 | 2025 | |
| Alimera Sciences, INC. | $441.61 | 2020-2024 | Iluvien, Yutiq |
| Regeneron Pharmaceuticals, INC. | $441.11 | 2019-2023 | Eylea, Eylea Hd |
| Apellis Pharmaceuticals, INC. | $292.09 | 2022-2023 | Syfovre |
| Astellas Pharma US INC | $184.96 | 2023 | |
| Allergan, INC. | $180.48 | 2020-2021 | |
| Genentech USA, INC. | $165.30 | 2022-2023 | Vabysmo |
| Abbvie INC. | $162.74 | 2022-2024 | |
| Genentech, INC. | $130.60 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $128.00 | 2021 | |
| Maculogix, INC. | $120.62 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $88.42 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $75.39 | 2022-2023 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $50.44 | 2019 | |
| Notal Vision, INC. | $37.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.80 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $32.60 | 2023 | Stellaris Elite |
| Carl Zeiss Meditec, INC. | $24.72 | 2021 | |
| Biogen, INC. | $24.10 | 2023 | |
| Vyera Pharmaceuticals, LLC | $22.32 | 2019 | |
| Spark Therapeutics, INC. | $20.00 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $18.71 | 2023 | Iheezo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nalin Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.